Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Regeneron (REGN) to $788 from $796 and keeps an Equal Weight rating on the shares. Pipeline progress continues to take precedence over quarterly performance, with upcoming Fianlimab Phase 3 melanoma data and FDA action on Eylea as the main areas of focus, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target lowered to $796 from $801 at Truist
- Regeneron price target lowered to $762 from $779 at RBC Capital
- Regeneron: Buy Rating Reiterated as Analyst Sees Melanoma Trial Sell-Off Overdone; $900 Price Target Unchanged
- Regeneron price target lowered to $917 from $923 at Barclays
- Regeneron Earnings Call Highlights Durable Growth Engine